Key insights
- Tango Therapeutics is set to report earnings amid optimism surrounding its cancer drug combination strategy, particularly vopimetostat. While short-term revenue is expected to decline, analysts are bullish on the stock, with a focus on the upcoming pivotal trial for MTAP-deleted pancreatic cancer. Stifel recently raised its price target, indicating increased conviction in the company's prospects. Overall, the news has a slightly positive influence on the US market.
Tango Therapeutics Inc. reports first-quarter earnings Wednesday, a milestone that comes as the clinical-stage biotech rides a wave of optimism around its cancer drug combination strategy but faces questions about its path to profitability.
The company, which focuses on precision oncology drugs targeting MTAP-deleted cancers, has a lead PRMT5 inhibitor called vopimetostat advancing through trials. Analysts expect Tango to report a loss of 31 cents per share on revenue of $636,000 for the March quarter, according to internal forecasts. That would represent a 13% year-over-year improvement in losses, though revenue is expected to decline 88% from the prior-year period.
Tango is one of the best performing healthcare stocks so far in 2026, with shares at $23.48, near the high end of its 52-week range of $1.25 to $28.41. The stock carries a market capitalization of $3.39 billion despite posting no profit. The company beat earnings expectations in its most recent quarter in March, reporting a loss of 29 cents per share versus the 32-cent loss forecast.
Analyst sentiment remains bullish. Eleven of 12 analysts rate the stock a buy, with a mean price target of $23.90—implying modest 1.8% upside from current levels. However, EPS estimates have edged down 2.9% over the past 60 days, while revenue estimates have declined 18% over the same period. Both estimates have held flat over the past week.
What Investors Are Watching
The real focus isn’t on quarterly results but on what comes next. In second-line pancreatic cancer, vopimetostat achieved a 25% overall response rate and a median progression-free survival of 7.2 months with a favorable safety profile in data reported last October. The company is accelerating toward a planned pivotal trial enrolling approximately 300 patients with MTAP-deleted pancreatic cancer starting in 2026.
But analysts are increasingly excited about combination therapy. Stifel raised its price target to $40 in late April, citing "increased conviction" for synergy between vopimetostat and RAS inhibitors in pancreatic cancer. Revolution Medicines’ daraxonrasib demonstrated statistically significant improvements in overall survival compared with chemotherapy in a Phase 3 trial, with median OS of 13.2 months versus 6.7 months.
That result validated RAS inhibitors as a backbone therapy for pancreatic cancer, boosting confidence in Tango’s strategy of combining its PRMT5 inhibitor with RAS drugs. Leerink Partners raised its price target to $28, increasing its probability of success estimates for Tango’s combination approach. First-in-human combination data is expected sometime in 2026—a potential catalyst that could support breakthrough designation from regulators.
The company reported $343 million in cash as of its last earnings update in March. With no revenue and continuing losses, investors will watch closely for commentary on cash runway and spending plans as pivotal trials loom.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.